The Scientific Link Between Senescent Cells, Aging, and Cancer. #science #aging #health #senescence

The original presentation is available for download as a PDF file from the link: https://drive.google.com/file/d/11AbjTOrO-eO-cgmsyf9EbNwYb9fEIqJW/view?usp=drive_link Компьютерный перевод текста презентации на русский язык также доступен: https://drive.google.com/file/d/1H2j9TvPnhn5jjqWDX5Uoq2oID6dQegue/view?usp=drive_link สามารถดาวน์โหลดคำแปลต้นฉบับเป็นภาษาไทยเป็นไฟล์ PDF ได้จากลิงก์: https://drive.google.com/file/d/1NfXOsn8QYHmFdEIrflzLj_CCrklgYC6Z/view?usp=drive_link Make money donations to get access to all my presentations and personal support by money transfer to the bank N26, IBAN: DE66 1001 1001 2670 2671 03; BIC NTSBDEB1XXX, owner: Irina Dumich or to PayPal: @drolegkulikov Contact me by Email: oleg.kulikow@gmail.com⁩ Cellular senescence, characterized by the accumulation of non-dividing but metabolically active "zombie" cells, is a fundamental hallmark of aging. These cells exert a profoundly deleterious effect via the Senescence-Associated Secretory Phenotype (SASP), a potent cocktail of pro-inflammatory cytokines, growth factors, and proteases. This secretion creates a state of chronic, low-grade inflammation—"inflammaging"—that drives tissue dysfunction and age-related pathology. Crucially, the relationship between senescent cells and cancer is complex and dualistic. While senescence initially acts as a tumor-suppressive mechanism by arresting damaged cells, the persistent SASP from these cells fosters a pro-tumorigenic microenvironment. It promotes the survival and proliferation of pre-malignant cells, stimulates angiogenesis, and facilitates invasion and metastasis. This creates a permissive landscape for cancer initiation. Furthermore, conventional cancer therapies like chemotherapy and radiotherapy induce senescence in tumor cells, leading to a surge in SASP. This explains the tragic paradox where cancer survivors often face accelerated aging and a heightened risk of cancer relapse or secondary malignancies, as the treatment itself fuels a disease-promoting environment. This mechanistic understanding has catalyzed the development of novel therapeutic strategies: senolytics and senostatics. Senolytics, such as the clinically validated combination of Dasatinib and Quercetin (D+Q), selectively eliminate senescent cells, reducing their burden and improving physical function. Ascorbic acid (vitamin C) also exhibits senolytic potential; megadoses, particularly via intravenous administration (25-75g), achieve high plasma concentrations and demonstrate anti-cancer efficacy. Oral megadoses (2-18g daily, fractionated) may modulate glycolysis and promote apoptosis in senescent and cancerous cells. Research also explores combinations like doxycycline with vitamin C to metabolically target cancer stem cells, and triple combinations (doxycycline, azithromycin, vitamin C) showing high senolytic efficacy *in vitro*. Conversely, senostatics, including Quercetin, Fisetin, Berberine, and Metformin, aim not to kill but to "muzzle" senescent cells by suppressing the harmful SASP, thereby mitigating its inflammatory and tumor-promoting effects. Adjunctive use of these agents during or after cancer treatment holds promise for reducing side effects, preventing relapse, and extending patient healthspan. Building on this science, a comprehensive personal protocol for healthspan extension and cancer prevention is proposed, integrating dietary, supplemental, and lifestyle interventions. The dietary foundation is a low-carbohydrate, carnivore-style diet aimed at reducing intestinal permeability and systemic inflammation. This is supported by glucose management with Berberine and continuous senostatic support via flavonoids like Quercetin and Fisetin. To selectively stress senescent cells, metabolic stressors such as High-Intensity Interval Training (HIIT) are employed. Supplementation includes metabolic cofactors (B vitamins, choline, betaine), agents for hormonal and sleep support (Niacin, Melatonin, Magnesium), and digestive aids like citric acid. The protocol emphasizes periodic, short-term senolytic interventions, such as with Fisetin, for radical rejuvenation, alongside the long-term use of fractionated, megadose vitamin C for senescent cell control and digestive health. Ancillary practices like sauna use and stress management complete the approach. In conclusion, cellular senescence represents a critical nexus linking aging and cancer. By targeting this common root through a multi-pronged strategy that combines senolytic clearance, senostatic suppression, metabolic optimization, and lifestyle modification, it is possible to concurrently decelerate the aging process and reduce the risk of malignant transformation, offering a unified framework for enhancing healthspan and resilience. **Keywords:** Cellular Senescence, SASP, Inflammaging, Cancer, Senolytics, Senostatics, Dasatinib, Quercetin, Fisetin, Vitamin C, Healthspan, Protocol.